UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 11, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 10/ 2026 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Executive Vice President, Chief Financial Officer (CFO) | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument, type of instrument, |
Shares |
||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Sale of shares | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 315.60 | 26,246 | |||
| d) |
Aggregated information
|
26,246 shares DKK 8,283,237.60 |
||
| e) | Date of the transaction | 2026-02-10 | ||
| f) | Place of the transaction | JANE STREET NETHERLANDS B.V. (JNSI) | ||
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 10/ 2026 |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Executive Vice President, Chief Financial Officer (CFO) | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the issuer | |||
| a) | Name | Novo Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details of the transaction(s) | |||
| a) | Description of the financial instrument, type of instrument, |
Shares |
||
| Identification code | Novo Nordisk B DK0062498333 | |||
| b) | Nature of the transaction | Sale of shares | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| DKK 315.70 | 311 | |||
| d) |
Aggregated information
|
311 shares DKK 98,182.70 |
||
| e) | Date of the transaction | 2026-02-10 | ||
| f) | Place of the transaction | CBOE EUROPE - DXE PERIODIC (NL) (BEUP) | ||
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| Max Ung +45 3077 6414 mxun@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Alex Bruce +45 3444 2613 axeu@novonordisk.com |
Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 10/ 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 11, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |